Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.35 |
| ▸ | KDM1A | O60341 | 9/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 8/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31140819 | 1.00 | MAOB (0.35) | MAOBKDM1APRCPTSHRTACR1 | |
| SCHEMBL3402260 | 0.84 | KDM1A (0.40) | MAOBKDM1APRCPTSHRTACR1 | |
| SCHEMBL20528510 | 0.84 | KDM1A (0.40) | MAOBKDM1APRCPTSHRTACR1 | |
| SCHEMBL20449202 | 0.83 | PRCP (0.38) | MAOBKDM1APRCPTSHRTACR1 | |
| SCHEMBL2707333 | 0.83 | PRCP (0.38) | MAOBKDM1APRCPTSHRTACR1 | |
| SCHEMBL20449208 | 0.83 | PRCP (0.38) | MAOBKDM1APRCPTSHRTACR1 | |
| SCHEMBL25318459 | 0.82 | — | — | |
| SCHEMBL31140836 | 0.82 | CTSC (0.33) | TSHR | |
| SCHEMBL25317695 | 0.82 | CTSC (0.33) | TSHR | |
| SCHEMBL31140818 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4469157-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| CN-118696035-A | Spiropiperidyl derivatives as complement factor B inhibitors and their use | 诺华股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | CFB, C1QBP, CFH | MAOB 98/4885KDM1A 4756/4885PRCP 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.